Skip to content

4 mg/ml

DRUG5 trials

Sponsors

Leiden University Medical Center, Stichting Radboud universitair medisch centrum, Leids Universitair Medisch Centrum (LUMC), Medical University Of Warsaw, Fondation Lenval Nice

Conditions

General anesthesiaLight chain amyloidosis (AL amyloidosis) is an incurable plasma cell neoplasm and the most common among a heterogeneous group of over 30 rare and ultra-rare diseases known as amyloidoses. In AL amyloidosis the deposition of amyloid fibrils resulting from misfolded immunoglobulin light chains leads to end-stage failure of the affected organsSEVERE ACUTE TRAUMA-RELATED PAINa 3-week treatment with sargramostim resulted in improved cognitive functiona relationship between high levels of GM-CSF in the synovial fluid and a lower risk of developing Alzheimer's diseasebased on the results of the ANDROMEDA phase III clinical trialclinical trials with opsonizing antibodies are ongoingcyclophosphamide and dexamethasone. The recombinant granulocyte macrophage colony stimulating factor (GM-CSF) sargramostim will be used in this study with the D-VCD regimen. Currently

Phase 2

Phase 4